Cause-specific death assessment of patients with stage I small-cell lung cancer: a competing risk analysis

被引：8
|
作者：
Liu, Jiaqing [1 ,2 ,3 ,4 ]
Zhou, Huaqiang [1 ,2 ,3 ,4 ]
Zhang, Yaxiong [1 ,2 ,3 ]
Fang, Wenfeng [1 ,2 ,3 ]
Yang, Yunpeng [1 ,2 ,3 ]
Hong, Shaodong [1 ,2 ,3 ]
Chen, Gang [1 ,2 ,3 ]
Zhao, Shen [1 ,2 ,3 ]
Chen, Xi [1 ,2 ,3 ]
Zhang, Zhonghan [1 ,2 ,3 ]
Xian, Wei [4 ]
Shen, Jiayi [4 ]
Huang, Yan [1 ,2 ,3 ]
Zhao, Hongyun [1 ,2 ,3 ]
Zhang, Li [1 ,2 ,3 ]
机构：
[1] Sun Yat Sen Univ, Ctr Canc, Dept Med Oncol, Guangzhou 510060, Guangdong, Peoples R China
[2] State Key Lab Oncol South China, Guangzhou 510060, Guangdong, Peoples R China
[3] Collaborat Innovat Ctr Canc Med, Guangzhou 510060, Guangdong, Peoples R China
[4] Sun Yat Sen Univ, Zhongshan Sch Med, Guangzhou 510080, Guangdong, Peoples R China
来源：
FUTURE ONCOLOGY | 2019年 / 15卷 / 21期
基金：
国家重点研发计划;
关键词：
cancer-specific death; competing risk nomogram; SCLC; SEER; SURVIVAL; SURGERY; COMORBIDITY; NOMOGRAM; OUTCOMES; LIMITATIONS; MORTALITY; PREDICT; IMPACT; NEED;
D O I：
10.2217/fon-2018-0888
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Aim: Stage I small-cell lung cancer (SCLC) is a potentially curable disease that needs timely and multidisciplinary management. The aim of this study was to evaluate the probability of cause-specific mortality for patients with stage I SCLC. Material & methods: We identified patients in the SEER database and constructed a proportional subdistribution hazard model to evaluate cancer-specific mortality. A nomogram was built based on Fine and Gray competing risk regression model. Results:A total of864 stage I SCLC patients were identified. The 5-year cumulative incidence of SCLC-specific mortality was 56.2%, while that for other causes of death was 17.3%. The c-index for the prognostic prediction model was 0.66. Besides, the nomogram was well calibrated. Conclusion: Our nomogram might serve as a reference for clinicians when evaluating the prognosis of stage I SCLC.
引用
收藏
页码：2479 / 2488
页数：10
相关论文
共 50 条
  • [41] Retrospective Analysis of Chemoradiotherapy for Limited-Stage Small-Cell Lung Cancer
    Lee, Jong Hoon
    Kim, Sung Hwan
    Kim, Su Zy
    Lee, Joo Hwan
    Kim, Hoon Kyo
    Shim, Byoung Yong
    RADIATION ONCOLOGY JOURNAL, 2009, 27 (03): : 133 - 139
  • [42] NON-SMALL-CELL LUNG-CANCER - MAJOR CAUSE OF LATE MORTALITY IN PATIENTS WITH SMALL-CELL LUNG-CANCER
    JOHNSON, BE
    IHDE, DC
    MATTHEWS, MJ
    BUNN, PA
    ZABELL, A
    MAKUCH, RW
    JOHNSTONEARLY, A
    COHEN, MH
    GLATSTEIN, E
    MINNA, JD
    AMERICAN JOURNAL OF MEDICINE, 1986, 80 (06): : 1103 - 1110
  • [43] Disease-specific survival for limited-stage small-cell lung cancer affected by statistical method of assessment
    Patricia Tai
    Judith-Anne W Chapman
    Edward Yu
    Dennie Jones
    Changhong Yu
    Fei Yuan
    Lee Sang-Joon
    BMC Cancer, 7
  • [44] Disease-specific survival for limited-stage small-cell lung cancer affected by statistical method of assessment
    Tai, Patricia
    Chapman, Judith-Anne W.
    Yu, Edward
    Jones, Dennie
    Yu, Changhong
    Yuan, Fei
    Sang-Joon, Lee
    BMC CANCER, 2007, 7
  • [45] A phase I study of amrubicin and carboplatin for previously untreated patients with extensive stage small-cell lung cancer
    Fukuda, M.
    Nakamura, Y.
    Kasai, T.
    Kinoshita, A.
    Fukuda, M.
    Motoshima, K.
    Iida, T.
    Nakatomi, K.
    Soda, H.
    Oka, M.
    Kohno, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [46] A phase I and pharmacological study of amrubicin and topotecan in patients of small-cell lung cancer with relapsed or extensive-disease small-cell lung cancer
    Shibayama, Takuo
    Hotta, Katsuyuki
    Takigawa, Nagio
    Tada, Atsuhiko
    Ueoka, Hiroshi
    Harita, Shingo
    Kiura, Katsuyuki
    Tabata, Masahiro
    Segawa, Yoshihiko
    Nogami, Naoyuki
    Kuyama, Shoichi
    Shinkai, Tetsu
    Tanimoto, Mitsune
    LUNG CANCER, 2006, 53 (02) : 189 - 195
  • [47] A retrospective analysis for the limited-stage small-cell lung cancer patients with combined modality treatment
    Zhou, Z.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (03): : S516 - S516
  • [48] Chemotherapy + ICIs in extensive-stage small-cell lung cancer: risk of interstitial lung disease
    Reactions Weekly, 2023, 1980 (1) : 5 - 5
  • [49] Paclitaxel for limited-stage small-cell lung cancer
    Greco, FA
    Hainsworth, JD
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (19) : 3453 - 3454
  • [50] Risk Factors in Patients with Pathological Stage I Non-Small Cell Lung Cancer
    Tokunaga, Yoshimasa
    Okamoto, Taku
    Chang, Sung Soo
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S662 - S662
12345